Novozymes stock
Price history
+11.37% over the period1 year: from kr 409.10 (November 17, 2025) to kr 455.60 (November 16, 2026), +11.37%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | kr 455.60 |
| October 30, 2026 | kr 462.00 |
| September 30, 2026 | kr 419.50 |
| August 31, 2026 | kr 462.40 |
| July 31, 2026 | kr 422.00 |
| June 30, 2026 | kr 412.90 |
| May 29, 2026 | kr 372.50 |
| April 30, 2026 | kr 390.90 |
| March 31, 2026 | kr 382.50 |
| February 27, 2026 | kr 375.50 |
| January 30, 2026 | kr 385.70 |
| December 30, 2025 | kr 407.80 |
| November 28, 2025 | kr 401.60 |
| November 17, 2025 | kr 409.10 |
At a glance
The company
Produce industrial enzymes, functional proteins, and microorganisms for food, beverage, bioenergy, cleaning, health, agriculture, and specialty applications
Latest results
Quarter to September 30, 2026 · EPS €4.04 (estimate €5.31)
TickerLandia's take on Novozymes
- Priced in line with similar companies: trailing 12-month P/E 42 vs 42 (+1%) in a group of 11.
- “Most upside for analysts” (Denmark): No. 10 of 21.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−6.00% from the 52-week high
Analysts · 15 analysts
Average targetkr 510.00+11.94% vs. price
Buy 11 · Hold 4 · Sell 0 · Buy
TickerLandia Fingerprint: Novozymes
Compared with similar companies: very high price.
Financials and price compared with 59 companies in the specialty chemicals industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery high81
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 42.1 70 Forward P/E 25.9 75 Price/book 2.56 62 EV/EBITDA 132.7 99 Price/sales 48.9 99 Profitabilityhigh66
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 56.3% 92 ROA 3.9% 35 Operating margin 23.4% 89 Net margin 15.6% 87 ROE 6.2% 28 Earnings stabilityhigh63
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.8% 60 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 65 Growthhigh70
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +20.78% 97 Earnings growth (year over year) +35.60% 75 Revenue growth (year over year) +7.10% 38 Financial strengthhigh62
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.78 58 Interest coverage 14.1 75 Current ratio 1.53 33 Debt/equitycounts in reverse: lower means more financial strength 0.28 81 Dividendaverage50
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 60.5% 59 Consecutive dividend years at least 26 years 61 Dividend yield 1.4% 31 Market momentumstrong61
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +9.34% 48 Distance from 200-day average +12.52% 74 Risklow38
How much the price swings.
Metric Value Position in group Volatility (60 days) 26.5% 48 Maximum drawdown (12 months) 19.0% 29
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Novozymes is in line with similar companies
Novozymes's P/E (trailing 12 months): 42.1, in line with the median of a group of 11 similar companies (41.7).
Compared with 11 similar companies
| Metric | Novozymes | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 42.1 | Middle | |
| Forward P/E | 25.9 | Middle | |
| Operating margin | 23.4% | High | |
| ROE | 6.2% | Middle | |
| Debt/equity | 0.28 | Low |
Grey band: the middle half of the group; tick: the median; dot: Novozymes. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€1.14B
Latest quarter · Q3 2026
Net income
€187.9M
Latest quarter · Q3 2026
Quarterly net margin
16.5%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- kr 213.94B
- P/E
- 42.1
- EPS
- kr 10.91
- Volume
- 493.73K
- Daily trading
- €43.79M
- Dividend yield
- 1.45%
- Last ex-dividend on August 25, 2026
How Novozymes is changing
All resultsRevenue grew 17.2% a year on average over the last 5 years
Operating margin fell from 25.5% to 23.1%
Profits turn into cash: free cash flow equal to 139% of net income
Returns
Novozymes returns with dividends
kr 1,000 invested in Novozymes 5 years ago, on November 16, 2021, would be worth kr 961 today with dividends reinvested: −3.91% in total, −0.80% per year. On price alone it would be kr 881 (−11.91%).
| Period | Novozymes | kr 1,000 becomes |
|---|---|---|
| 1 month | +0.18% | kr 1,002 |
| 6 months | +20.47% | kr 1,205 |
| Year to date | +11.72% | kr 1,117 |
| 1 year | +13.28% | kr 1,133 |
| 3 years | +34.44% | kr 1,344 |
| 5 years | −3.91% | kr 961 |
| 10 years | +121.05% | kr 2,210 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Novozymes: technical analysis
Novozymes is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 15.2% below its all-time closing high (kr 537.20, December 30, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 50
- Between 30 and 70
- vs 200-session average
- +11.62%
Support and resistance
Price areas where Novozymes has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistancekr 483.10+6.04%2 touches, last on November 5, 2026
- Last pricekr 455.60
- Supportkr 432.30−5.11%2 touches, last on July 17, 2026
- Supportkr 426.12−6.47%6 touches, last on September 18, 2026
- Supportkr 409.00−10.23%3 touches, last on October 2, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 26.4%
- Largest fall in the last year
- −19.00%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Novozymes: seasonality
Average monthly price change over 26 years
Over the last 26 years, the strongest month for Novozymes has been May: +3.51% on average, positive in 20 years out of 26. The weakest has been January: −0.87% on average, positive in 13 years out of 26. November, the current month, has been positive in 13 years out of 25 (+1.49% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.87% | −0.08% | 13 of 26 |
| February | +3.13% | +3.14% | 19 of 26 |
| March | +1.14% | +1.65% | 14 of 26 |
| April | +2.79% | +2.85% | 17 of 26 |
| May | +3.51% | +3.48% | 20 of 26 |
| June | −0.74% | −0.97% | 12 of 26 |
| July | +2.44% | +2.18% | 19 of 26 |
| August | −0.47% | 0.00% | 13 of 26 |
| September | −0.75% | +0.28% | 14 of 26 |
| October | −0.02% | +1.55% | 14 of 26 |
| November | +1.49% | +1.28% | 13 of 25 |
| December | +1.54% | +1.69% | 17 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Novozymes and its competitors
Based in Lyngby, Denmark, and founded in 1925, the company develops and supplies enzymes, functional proteins and microorganisms to industrial customers. Its biosolutions serve food and beverage makers, from dairy and baking to plant-based foods, and it also supplies ethanol, biodiesel, biogas and renewable diesel producers. Other product lines cover household and industrial cleaning, human health supplements, agricultural crop and animal solutions, pet care, and leather and textile processing. Sales reach Denmark, the rest of Europe, North America, Asia Pacific, the Middle East, Africa and Latin America.
- Headquarters
- Lyngby, Denmark
- Employees
- 10,933
- Founded
- 1925
- Chief executive
- Ester Baiget
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| NovozymesNSIS.B | $31.63B | 23.4% | 42.1 | +20.47% |
| DSM-FirmenichDSFIR | $28.52B | 6.8% | 63.4 | +57.73% |
| SikaSIKA | $36.73B | 13.6% | 29.6 | +38.19% |
| EMS-CHEMIE HOLDINGEMSN | $23.88B | 29.9% | 42.3 | +28.25% |
| GivaudanGIVN | $45.03B | 17.9% | 39.8 | +51.26% |
| SymriseSY1 | $14.06B | 12.6% | 52.6 | +29.50% |
Same industry or related industries, similar size. Compare Novozymes with its competitors · Full profile
